Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Soluble SLAMF6 Receptor Induces Strong CD8+ T-cell Effector Function and Improves Anti-Melanoma Activity In Vivo.

Eisenberg G, Engelstein R, Geiger-Maor A, Hajaj E, Merims S, Frankenburg S, Uzana R, Rutenberg A, Machlenkin A, Frei G, Peretz T, Lotem M.

Cancer Immunol Res. 2018 Feb;6(2):127-138. doi: 10.1158/2326-6066.CIR-17-0383. Epub 2018 Jan 5.

PMID:
29305520
2.

Phenotype-based variation as a biomarker of sensitivity to molecularly targeted therapy in melanoma.

Senses KM, Ghasemi M, Akbar MW, Isbilen M, Fallacara AL, Frankenburg S, Schenone S, Lotem M, Botta M, Gure AO.

Medchemcomm. 2017 Jan 1;8(1):88-95. doi: 10.1039/C6MD00466K. Epub 2016 Oct 27.

3.

Immune Monitoring of Patients Treated With a Whole-Cell Melanoma Vaccine Engineered to Express 4-1BBL.

Engelstein R, Merims S, Eisenberg G, Cohen J, Frank S, Hamburger T, Frankenburg S, Ron I, Isacson R, Grenader T, Steinberg H, Cohen CJ, Peretz T, Lotem M.

J Immunother. 2016 Oct;39(8):321-8. doi: 10.1097/CJI.0000000000000138.

PMID:
27564312
4.

Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade.

Lotem M, Merims S, Frank S, Hamburger T, Nissan A, Kadouri L, Cohen J, Straussman R, Eisenberg G, Frankenburg S, Carmon E, Alaiyan B, Shneibaum S, Ozge Ayyildiz Z, Isbilen M, Mert Senses K, Ron I, Steinberg H, Smith Y, Shiloni E, Gure AO, Peretz T.

J Immunol Res. 2016;2016:8121985. doi: 10.1155/2016/8121985. Epub 2016 May 18.

5.

Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells.

Pato A, Eisenberg G, Machlenkin A, Margalit A, Cafri G, Frankenburg S, Merims S, Peretz T, Lotem M, Gross G.

Clin Exp Immunol. 2015 Nov;182(2):220-9. doi: 10.1111/cei.12688. Epub 2015 Aug 28.

6.

Human T cell crosstalk is induced by tumor membrane transfer.

Uzana R, Eisenberg G, Merims S, Frankenburg S, Pato A, Yefenof E, Engelstein R, Peretz T, Machlenkin A, Lotem M.

PLoS One. 2015 Feb 11;10(2):e0118244. doi: 10.1371/journal.pone.0118244. eCollection 2015.

7.

Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells.

Eisenberg G, Uzana R, Pato A, Frankenburg S, Merims S, Yefenof E, Ferrone S, Peretz T, Machlenkin A, Lotem M.

J Immunol. 2013 Jun 1;190(11):5856-65. doi: 10.4049/jimmunol.1202879. Epub 2013 Apr 26.

8.

Trogocytosis is a gateway to characterize functional diversity in melanoma-specific CD8+ T cell clones.

Uzana R, Eisenberg G, Sagi Y, Frankenburg S, Merims S, Amariglio N, Yefenof E, Peretz T, Machlenkin A, Lotem M.

J Immunol. 2012 Jan 15;188(2):632-40. doi: 10.4049/jimmunol.1101429. Epub 2011 Dec 7.

9.

HLA-B35 correlates with a favorable outcome following adjuvant administration of an HLA-matched allogeneic melanoma vaccine.

Lotem M, Kadouri L, Merims S, Ospovat I, Nissan A, Ron I, Frankenburg S, Machlenkin A, Israel S, Steinberg H, Hamburger T, Peretz T.

Tissue Antigens. 2011 Sep;78(3):203-7. doi: 10.1111/j.1399-0039.2011.01709.x. Epub 2011 Jun 7.

PMID:
21644933
10.

Transcutaneous immunization with hydrophilic recombinant gp100 protein induces antigen-specific cellular immune response.

Eisenberg G, Machlenkin A, Frankenburg S, Mansura A, Pitcovski J, Yefenof E, Peretz T, Lotem M.

Cell Immunol. 2010;266(1):98-103. doi: 10.1016/j.cellimm.2010.09.003. Epub 2010 Sep 18.

11.

Apheresis induces oxidative stress in blood cells.

Amer J, Frankenburg S, Fibach E.

Ther Apher Dial. 2010 Apr;14(2):166-71. doi: 10.1111/j.1744-9987.2009.00746.x.

PMID:
20438538
12.

Autologous melanoma vaccine induces antitumor and self-reactive immune responses that affect patient survival and depend on MHC class II expression on vaccine cells.

Lotem M, Machlenkin A, Hamburger T, Nissan A, Kadouri L, Frankenburg S, Gimmon Z, Elias O, David IB, Kuznetz A, Shiloni E, Peretz T.

Clin Cancer Res. 2009 Aug 1;15(15):4968-77. doi: 10.1158/1078-0432.CCR-08-3320. Epub 2009 Jul 14.

13.

Capture of tumor cell membranes by trogocytosis facilitates detection and isolation of tumor-specific functional CTLs.

Machlenkin A, Uzana R, Frankenburg S, Eisenberg G, Eisenbach L, Pitcovski J, Gorodetsky R, Nissan A, Peretz T, Lotem M.

Cancer Res. 2008 Mar 15;68(6):2006-13. doi: 10.1158/0008-5472.CAN-07-3119.

14.

A melanoma multiepitope polypeptide induces specific CD8+ T-cell response.

Levy A, Pitcovski J, Frankenburg S, Elias O, Altuvia Y, Margalit H, Peretz T, Golenser J, Lotem M.

Cell Immunol. 2007 Nov-Dec;250(1-2):24-30. doi: 10.1016/j.cellimm.2008.01.001. Epub 2008 Feb 13.

15.

Immunological activation following transcutaneous delivery of HR-gp100 protein.

Frankenburg S, Grinberg I, Bazak Z, Fingerut L, Pitcovski J, Gorodetsky R, Peretz T, Spira RM, Skornik Y, Goldstein RS.

Vaccine. 2007 Jun 6;25(23):4564-70. Epub 2007 Apr 25.

16.

Heat labile enterotoxin of E. coli: a potential adjuvant for transcutaneous cancer immunotherapy.

Pitcovski J, Bazak Z, Wasserman E, Elias O, Levy A, Peretz T, Fingerut E, Frankenburg S.

Vaccine. 2006 Jan 30;24(5):636-43. Epub 2005 Aug 30.

PMID:
16157421
17.

Recombinant hydrophilic human gp100: uptake by dendritic cells and stimulation of autologous CD8+ lymphocytes from melanoma patients.

Frankenburg S, Elias O, Gelbart Y, Drize O, Lotem M, Ingber A, Peretz T, Pitcovski J.

Immunol Lett. 2004 Jul 15;94(3):253-9.

PMID:
15275974
18.

Production and purification of melanoma gp100 antigen and polyclonal antibodies.

Gelbart Y, Frankenburg S, Pinchasov Y, Krispel S, Eliahu D, Drize O, Morag E, Bartfeld D, Lotem M, Peretz T, Pitcovski J.

Protein Expr Purif. 2004 Apr;34(2):183-9.

PMID:
15003249
19.

Interleukin-2 improves tumour response to DNP-modified autologous vaccine for the treatment of metastatic malignant melanoma.

Lotem M, Shiloni E, Pappo I, Drize O, Hamburger T, Weitzen R, Isacson R, Kaduri L, Merims S, Frankenburg S, Peretz T.

Br J Cancer. 2004 Feb 23;90(4):773-80.

20.

Topical treatment of persistent cutaneous leishmaniasis with ethanolic lipid amphotericin B.

Zvulunov A, Cagnano E, Frankenburg S, Barenholz Y, Vardy D.

Pediatr Infect Dis J. 2003 Jun;22(6):567-9.

PMID:
12828157
21.

[Treatment of cutaneous leishmaniasis--an update].

Vardy DA, Gilead L, Frankenburg S.

Harefuah. 2002 Jan;141(1):70-5, 125, 124. Review. Hebrew.

PMID:
11851113
22.

Efficacious topical treatment for human cutaneous leishmaniasis with ethanolic lipid amphotericin B.

Vardy D, Barenholz Y, Naftoliev N, Klaus S, Gilead L, Frankenburg S.

Trans R Soc Trop Med Hyg. 2001 Mar-Apr;95(2):184-6. No abstract available.

PMID:
11355557
23.

Relapse of cutaneous leishmaniasis in a patient with an infected subcutaneous rheumatoid nodule.

Vardy DA, Cohen A, Kachko L, Zvulunov A, Frankenburg S.

Br J Dermatol. 1999 Nov;141(5):914-7.

PMID:
10583179
24.

Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives.

Golenser J, Frankenburg S, Ehrenfreund T, Domb AJ.

Antimicrob Agents Chemother. 1999 Sep;43(9):2209-14.

25.

Topical amphotericin B for cutaneous leishmaniasis.

Vardy D, Barenholz Y, Cohen R, Zvulunov A, Biton A, Klaus S, Frankenburg S.

Arch Dermatol. 1999 Jul;135(7):856-7. No abstract available.

PMID:
10411171
26.

Epidemiology of cutaneous leishmaniasis.

Klaus SN, Frankenburg S, Ingber A.

Clin Dermatol. 1999 May-Jun;17(3):257-60. Review. No abstract available.

PMID:
10384863
27.

Cutaneous leishmaniasis in the Middle East.

Klaus S, Frankenburg S.

Clin Dermatol. 1999 Mar-Apr;17(2):137-41; discussion 105-6. No abstract available.

PMID:
10330596
28.

Efficacious topical treatment for murine cutaneous leishmaniasis with ethanolic formulations of amphotericin B.

Frankenburg S, Glick D, Klaus S, Barenholz Y.

Antimicrob Agents Chemother. 1998 Dec;42(12):3092-6.

29.

Vitamin A inhibits cytokines produced by type 1 lymphocytes in vitro.

Frankenburg S, Wang X, Milner Y.

Cell Immunol. 1998 Apr 10;185(1):75-81.

PMID:
9636685
30.

Effective immunization of mice against cutaneous leishmaniasis using an intrinsically adjuvanted synthetic lipopeptide vaccine.

Frankenburg S, Axelrod O, Kutner S, Greenblatt CL, Klaus SN, Pirak EA, McMaster R, Lowell GH.

Vaccine. 1996 Jun;14(9):923-9.

PMID:
8843636
31.

Imbalance of immune responses in patients with chronic and widespread fungal skin infection.

Leibovici V, Evron R, Axelrod O, Westerman M, Shalit M, Barak V, Frankenburg S.

Clin Exp Dermatol. 1995 Sep;20(5):390-4.

PMID:
8593715
32.

Changing patterns of cutaneous leishmaniasis in Israel and neighbouring territories.

Klaus S, Axelrod O, Jonas F, Frankenburg S.

Trans R Soc Trop Med Hyg. 1994 Nov-Dec;88(6):649-50.

PMID:
7886757
33.

Antigen presentation by epidermal Langerhans cells in experimental cutaneous leishmaniasis.

Axelrod O, Klaus S, Frankenburg S.

Parasite Immunol. 1994 Nov;16(11):593-8.

PMID:
7862465
34.

Serial study of the immune response of an individual with exacerbated simple cutaneous leishmaniasis.

Klaus SN, Frankenburg S, Gross A, Jonas F, Vardy D.

Isr J Med Sci. 1994 Jan;30(1):19-21.

PMID:
8138392
35.
36.

Gorging response of culicine mosquitoes (Diptera: Culicidae) to blood fractions.

Galun R, Vardimon-Friedman H, Frankenburg S.

J Med Entomol. 1993 May;30(3):513-7.

PMID:
8510110
37.

Development of in vitro parameters of cell-mediated immunity in the course of human cutaneous leishmaniasis infection.

Frankenburg S, Jonas F, Gross A, Klaus S.

Am J Trop Med Hyg. 1993 Apr;48(4):512-8.

PMID:
8480859
38.

Effect of topical paromomycin on cell-mediated immunity during cutaneous leishmaniasis.

Frankenburg S, Gross A, Jonas F, Klaus S.

Int J Dermatol. 1993 Jan;32(1):68-70.

PMID:
8425810
39.

Unusually extensive disease caused by Leishmania major parasites.

Vardy DA, Frankenburg S, Goldenhersh M, Leibovici V, Klaus SN.

Clin Exp Dermatol. 1993 Jan;18(1):36-40.

PMID:
8382568
40.
41.
42.

Cutaneous leishmaniasis acquired during military service in the Middle East.

Norton SA, Frankenburg S, Klaus SN.

Arch Dermatol. 1992 Jan;128(1):83-7. Review.

PMID:
1739291
43.

Human cutaneous leishmaniasis: in-vitro parasite--mononuclear cell interactions in immune and naive individuals.

Gross A, Sliwa K, Frankenburg S, Wyler D, Klaus S.

Arch Dermatol Res. 1992;284(4):209-11.

PMID:
1417066
44.
45.

Effect of glycolipids of Leishmania parasites on human monocyte activity. Inhibition by lipophosphoglycan.

Frankenburg S, Leibovici V, Mansbach N, Turco SJ, Rosen G.

J Immunol. 1990 Dec 15;145(12):4284-9.

PMID:
2147940
46.

Evaluation of a total lymphocyte proliferation assay as a diagnostic tool for cutaneous leishmaniasis.

Frankenburg S, Klaus S.

Trans R Soc Trop Med Hyg. 1989 Jul-Aug;83(4):499-502.

PMID:
2617599
47.

Delayed-type hypersensitivity and lymphocyte proliferation in response to Leishmania major infection in a group of children in Jericho.

Alvarado R, Enk C, Jaber K, Schnur L, Frankenburg S.

Trans R Soc Trop Med Hyg. 1989 Mar-Apr;83(2):189-92.

PMID:
2609368
48.
49.
50.

Supplemental Content

Loading ...
Support Center